Division of Nephrology and Hypertension, University of Cape Town, Cape Town, South Africa.
Department of Medicine, Princess Marina Hospital, Gaborone, Botswana.
BMJ Open. 2018 May 24;8(5):e020464. doi: 10.1136/bmjopen-2017-020464.
Continuous ambulatory peritoneal dialysis (CAPD) is the ideal modality for renal replacement therapy in most African settings given that it is relatively cheaper than haemodialysis (HD) and does not require in-centre care. CAPD is, however, not readily utilised as it is often complicated by peritonitis leading to high rates of technique failure. The objective of this study is to assess the prevalence of CAPD-related peritonitis and all-cause mortality in patients treated with CAPD in Africa.
We will search PubMed, EMBASE, SCOPUS, Africa Journal Online and Google Scholar for studies conducted in Africa from 1 January 1980 to 30 June 2017 with no language restrictions. Eligible studies will include cross-sectional, prospective observational and cohort studies of patients treated with CAPD. Two authors will independently screen, select studies, extract data and conduct risk of bias assessment. Data consistently reported across studies will be pooled using random-effects meta-analysis. Heterogeneity will be evaluated using Cochrane's Q statistic and quantified using I statistics. Graphical and formal statistical tests will be used to assess for publication bias.
Ethical approval will not be needed for this study as data used will be extracted from already published studies. Results of this review will be published in a peer-reviewed journal and presented at conferences. The Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015) framework guided the development of this protocol.
CRD42017072966.
在大多数非洲地区，连续不卧床腹膜透析（CAPD）是肾脏替代治疗的理想方式，因为它比血液透析（HD）相对便宜，且不需要中心护理。然而，由于 CAPD 常因腹膜炎而导致技术失败率高，因此并未广泛应用。本研究旨在评估非洲地区接受 CAPD 治疗的患者中 CAPD 相关腹膜炎和全因死亡率的流行情况。
我们将在 PubMed、EMBASE、SCOPUS、Africa Journal Online 和 Google Scholar 上搜索 1980 年 1 月 1 日至 2017 年 6 月 30 日期间在非洲进行的研究，无语言限制。合格的研究将包括接受 CAPD 治疗的患者的横断面、前瞻性观察性和队列研究。两位作者将独立筛选、选择研究、提取数据并进行偏倚风险评估。使用随机效应荟萃分析对一致报告的研究数据进行汇总。使用 Cochrane's Q 统计量评估异质性，并使用 I 统计量量化。将使用图形和正式统计检验来评估发表偏倚。
本研究不需要伦理批准，因为使用的数据将从已发表的研究中提取。本综述的结果将发表在同行评议的期刊上，并在会议上展示。本研究方案遵循系统评价和荟萃分析的首选报告项目 2015 年（PRISMA-P 2015）框架。
PROSPERO 注册号：CRD42017072966。
